TRVI Insider Trading
Insider Ownership Percentage: 24.37%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $897,979.71
Trevi Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Trevi Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Trevi Therapeutics Share Price & Price History
Current Price: $6.75
Price Change: ▲ Price Increase of +0.46 (7.31%)
As of 03/14/2025 05:00 PM ET
Trevi Therapeutics Insider Trading History
Trevi Therapeutics Institutional Trading History
Data available starting January 2016
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Read More on Trevi Therapeutics
Volume
1,915,221 shs
Average Volume
2,023,841 shs
Market Capitalization
$518.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.9
Who are the company insiders with the largest holdings of Trevi Therapeutics?
Who are the major institutional investors of Trevi Therapeutics?
Which major investors are selling Trevi Therapeutics stock?
In the last quarter, TRVI stock was sold by these institutional investors:
- VR Adviser LLC
- Ally Bridge Group NY LLC
- Landscape Capital Management L.L.C.
- Tejara Capital Ltd
- Marshall Wace LLP
- Algert Global LLC
- Bridgeway Capital Management LLC
- Citadel Advisors LLC
During the last year, company insiders that have sold Trevi Therapeutics company stock include:
- David P Meeker (Director)
- Thomas Sciascia (Insider)
- Jennifer L Good (CEO)
- Farrell Simon (Insider)
- Lisa Delfini (CFO)
Learn More investors selling Trevi Therapeutics stock.
Which major investors are buying Trevi Therapeutics stock?
Within the last quarter, TRVI stock was purchased by institutional investors including:
- Point72 Asset Management L.P.
- Frazier Life Sciences Management L.P.
- Woodline Partners LP
- Adage Capital Partners GP L.L.C.
- Acorn Capital Advisors LLC
- Vivo Capital LLC
- MPM Bioimpact LLC
- Acuta Capital Partners LLC